10[9]Poli D,Antonucei E,Cecchi E,et al.Culprit factors for the failure of well-conducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation:the role of homocysteine[J].Stroke,2005,36(10):2159-2163. 被引量：1
2Gage BF,Eby C,Johnson JA,et al.Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin[J].Clin Pharmacol Ther,2008,84(3):326-331. 被引量：1
3Hirsh J,Fuster V,Ansell J,et al.American heart associ ation/American college of cardiology foundation guide to warfarin therapy[J].J Am Coll Cardiol,2003,41(9):1633-1652. 被引量：1
4Fuster V,Ryden LE,Cannom DS,et al.2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation:a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J].Circulation,2011,123(10):e269-e367. 被引量：1
5Fuster V,Ryden LE,Cannom DS,et al.ACC/AHA/ESC 2006 Guidelines for the Management of Patient with Atrial Fibrillation:a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines(Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation):developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society[J].Circulation,2006,114(7):e257-e354. 被引量：1
6Horne BD,Lenzini PA,Wadelius M,et al.Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy[J].Thromb Haemost,2012,107(2):232-234. 被引量：1
7CHRISTIANWEISS,ANDREASGOCHT,STEPHANWILLEMS,MATTHIASHOFFMANN,TIMRISIUS,THOMASMEINERTZ.??Impact of the Distribution and Structure of Myocardium in the Pulmonary Veins for Radiofrequency Ablation of Atrial Fibrillation(J)Pacing and Clinical Electrophysiology . 2003 (9) 被引量：1
